Targeting Bcl-2 with oblimersen for patients with hormone refractory prostate cancer

被引:11
作者
Chi, KN [1 ]
机构
[1] British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada
关键词
Bcl-2; oblimersen; hormone refractory prostate cancer;
D O I
10.1007/s00345-004-0477-x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Patients with metastatic hormone refractory prostate cancer (HRPC) have limited treatment options and new therapies are needed. Advances in the understanding of the molecular mechanisms implicated in prostate cancer progression have identified many potential therapeutic gene targets including Bcl-2, an important pro-survival regulator of apoptotic cell death. Bcl-2 is overexpressed in a variety of human malignancies including prostate cancer where it has also been associated with androgen independent progression and treatment resistance. Oblimersen is a phosphorothioate antisense oligonucleotide complimentary to the Bcl-2 mRNA and a potent inhibitor of Bcl-2 expression which in pre-clinical testing can significantly enhance the therapeutic effect of chemotherapy, hormone and radiation therapy. Clinical trials evaluating oblimersen in combination with chemotherapy in a variety of cancers have shown good tolerability and promising response rates. Randomized trials are required to determine if oblimersen can enhance the effectiveness of docetaxel in patients with HRPC.
引用
收藏
页码:33 / 37
页数:5
相关论文
共 41 条
  • [1] Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer
    Beer, TM
    Pierce, WC
    Lowe, BA
    Henner, WD
    [J]. ANNALS OF ONCOLOGY, 2001, 12 (09) : 1273 - 1279
  • [2] Bubendorf L, 1996, AM J PATHOL, V148, P1557
  • [3] Carpentier AF, 1999, CANCER RES, V59, P5429
  • [4] Effects of Bcl-2 modulation with G3139 antisense oligonucleotide on human breast cancer cells are independent of inherent Bcl-2 protein expression
    Chi, KN
    Wallis, AE
    Lee, CH
    de Menezes, DL
    Sartor, J
    Dragowska, WH
    Mayer, LD
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2000, 63 (03) : 199 - 212
  • [5] Chi KN, 2001, CLIN CANCER RES, V7, P3920
  • [6] CHI KN, 2003, P AM SOC CLIN ONC 37
  • [7] COLOMBEL M, 1993, AM J PATHOL, V143, P390
  • [8] Molecular mechanisms of antisense drugs: RNase H
    Crooke, ST
    [J]. ANTISENSE & NUCLEIC ACID DRUG DEVELOPMENT, 1998, 8 (02): : 133 - 134
  • [9] de Menezes DEL, 2000, CLIN CANCER RES, V6, P2891
  • [10] DEBONO JS, 2001, P AM SOC CLIN ONC 37